Abnova (Taiwan)TPE:4133 -1.46%75 FCF Margin % is 13.19% as of Dec. 2025, which is 7% above its 10-year median of 12.27. GuruFocus rates TPE:4133 with a GF Score™ of 75/100 and a GF Value™ of NT$28.30 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 959 Biotechnology companies, Abnova (Taiwan) ranks better than 73.1% on this metric.
The historical rank and industry rank for Abnova (Taiwan)'s FCF Margin % or its related term are showing as below:
TPE:4133'
s FCF Margin % Range Over the Past 10 Years
Min: -4.31 Med: 12.27 Max: 30.61
Current: -2.85
During the past 13 years, the highest FCF Margin % of Abnova (Taiwan) was 30.61%. The lowest was -4.31%. And the median was 12.27%.
TPE:4133's FCF Margin % is ranked better than 73.1% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs TPE:4133: -2.85
Abnova (Taiwan) FCF Margin % Related Terms
Abnova (Taiwan) FCF Margin % Historical Data
* Premium members only.
The historical data trend for Abnova (Taiwan)'s FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4133 vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Abnova (Taiwan)'s FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abnova (Taiwan) FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abnova (Taiwan)'s FCF Margin % distribution charts can be found below:
* The bar in red indicates where Abnova (Taiwan)'s FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abnova (Taiwan) (TPE:4133) has a FCF Margin % of 13.19% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Abnova (Taiwan) and its competitors. This is near median its historical median of 12.27. According to the industry distribution chart, Abnova (Taiwan) ranks #258 out of 959 companies in the Biotechnology industry, placing it in the top 26.9%.
Is Abnova (Taiwan)'s FCF Margin % too high?
Abnova (Taiwan)'s current FCF Margin % of 13.19% is near median its 10-year median of 12.27. Based on the distribution chart, Abnova (Taiwan) ranks #258 out of 959 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Abnova (Taiwan) has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abnova (Taiwan)'s FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abnova (Taiwan) ranks #258 out of 959 companies for FCF Margin %. This puts Abnova (Taiwan) in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Abnova (Taiwan) and its competitors. Abnova (Taiwan)'s current FCF Margin % is 13.19%, which is near median its own 10-year median of 12.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abnova (Taiwan) stock overvalued right now?
Based on GuruFocus' analysis, Abnova (Taiwan) (TPE:4133) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$28.30, compared to a current price of NT$20.25 — trading 28.4% below its estimated fair value. The current FCF Margin % is 13.19%, which is near median its 10-year median of 12.27. Abnova (Taiwan)'s overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Abnova (Taiwan) (TPE:4133), the current FCF Margin % is 13.19% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abnova (Taiwan) (TPE:4133) Overvalued in 2026?
Based on GuruFocus' analysis, Abnova (Taiwan) stock appears to be undervalued.
The current stock price of NT$20.25 is trading 28.4% below its estimated GF Value™ of NT$28.30.
GuruFocus considers Abnova (Taiwan) to be Modestly Undervalued.
Key valuation signals for TPE:4133:
FCF Margin %: 13.19% (near median its 10-year median of 12.27)
GF Value™: NT$28.30 vs. price of NT$20.25 (28.4% below fair value)
No single metric tells the full story. See the TPE:4133 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abnova (Taiwan) Corp is engaged in developing, manufacturing, and selling monoclonal antibody, polyclonal antibody, proteins, medical inspection instruments and testing reagents, which are mainly antibody reagents, antibody chips or related products provided to and used by academic, research institutions or pharmaceutical factories. Geographically, it operates in America, Europe, Taiwan and Other Countries. It generates maximum revenue from America. Its products include: SARS-CoV/CoV-2, DNA, RNA new, Proteins/peptides, MaxPab, DNAxPab, Polyclonal Ab, Monoclonal Ab and Others. The company's services are: Gene synthesis & cytogenetics, Peptide services, Protein expression, Humanized antibody, Assay development, Conjugation, FFPE tumor tissue DNA, In situ hybridization (ISH) and Others.
75GF Score
Get the complete analysis for TPE:4133
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4133 has been successfully added to your 
